SANES

10.488

-0.11%↓

BBVA

19.37

+0.83%↑

BNP

89.93

+0.95%↑

CABK

11.445

+0.35%↑

INGA

26.45

+1.24%↑

SANES

10.488

-0.11%↓

BBVA

19.37

+0.83%↑

BNP

89.93

+0.95%↑

CABK

11.445

+0.35%↑

INGA

26.45

+1.24%↑

SANES

10.488

-0.11%↓

BBVA

19.37

+0.83%↑

BNP

89.93

+0.95%↑

CABK

11.445

+0.35%↑

INGA

26.45

+1.24%↑

SANES

10.488

-0.11%↓

BBVA

19.37

+0.83%↑

BNP

89.93

+0.95%↑

CABK

11.445

+0.35%↑

INGA

26.45

+1.24%↑

SANES

10.488

-0.11%↓

BBVA

19.37

+0.83%↑

BNP

89.93

+0.95%↑

CABK

11.445

+0.35%↑

INGA

26.45

+1.24%↑

Home・Akcijų sąrašas・Ipsen SA.

Ipsen SA.

Uždarymo kaina

SektoriusFinansų sektorius

159 -1.55

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

159

Max

160.1

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-225M 110M
Pardavimai	36M 1.9B
P/E Sektoriaus vid.	29.171 58.236
Dividendų pajamingumas	0.84
Pelno marža	5.899
Darbuotojai	5,535
EBITDA	-171M 466M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-10.24% downside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	0.84% 4.64%
Kitas uždarbis	2026-07-30

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1.4B 13B
Ankstesnė atidarymo kaina	160.55
Ankstesnė uždarymo kaina	159

Naujienos nuotaikos

By Acuity

65%

35%

366 / 438 reitingas Finance

Ipsen SA. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-22 16:33; UTC

Uždarbis

Pagrindinės rinkos jėgos

Webull Shares Slide on 1Q Loss, Soaring Costs

2026-05-23 08:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-05-23 08:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-23 08:00; UTC

Uždarbis

AI Could Kill the Brokerage Industry's Cash Cow -- Barrons.com

2026-05-23 05:58; UTC

Uždarbis

Our Cadre Holdings Pick Has Disappointed. We're Sticking With It. -- Barrons.com

2026-05-22 21:10; UTC

Uždarbis

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

2026-05-22 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-22 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-05-22 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-22 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-22 19:47; UTC

Uždarbis

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

2026-05-22 19:17; UTC

Rinkos pokalbiai

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

2026-05-22 19:10; UTC

Rinkos pokalbiai

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

2026-05-22 18:54; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-22 18:54; UTC

Rinkos pokalbiai

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

2026-05-22 18:38; UTC

Rinkos pokalbiai

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

2026-05-22 18:35; UTC

Įsigijimai, susijungimai, perėmimai

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

2026-05-22 18:09; UTC

Rinkos pokalbiai

Centralized Crypto Lending Slows in 1Q -- Market Talk

2026-05-22 17:58; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

2026-05-22 17:54; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2026-05-22 17:54; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-22 17:54; UTC

Rinkos pokalbiai

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

2026-05-22 17:03; UTC

Rinkos pokalbiai

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

2026-05-22 16:54; UTC

Rinkos pokalbiai

Crypto Spot Volumes Fall 14% in April -- Market Talk

2026-05-22 16:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-05-22 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-22 16:20; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-05-22 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-22 16:16; UTC

Rinkos pokalbiai

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

2026-05-22 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Ipsen SA. Prognozė

Kainos tikslas

By TipRanks

-10.24% į apačią

12 mėnesių prognozė

Vidutinis 143.8 EUR -10.24%

Aukščiausias 170 EUR

Žemiausias 117 EUR

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ipsen SA. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Ipsen SA. akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

366 / 438 reitingas Finansų sektorius

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.